259 related articles for article (PubMed ID: 29934755)
1. Cytotoxic Effects of 3,4-Catechol-PV (One Major MDPV Metabolite) on Human Dopaminergic SH-SY5Y Cells.
Coccini T; Vecchio S; Crevani M; De Simone U
Neurotox Res; 2019 Jan; 35(1):49-62. PubMed ID: 29934755
[TBL] [Abstract][Full Text] [Related]
2. Synthetic Cathinones Induce Cell Death in Dopaminergic SH-SY5Y Cells via Stimulating Mitochondrial Dysfunction.
Leong HS; Philp M; Simone M; Witting PK; Fu S
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32085614
[TBL] [Abstract][Full Text] [Related]
3. Neurotoxicity of β-Keto Amphetamines: Deathly Mechanisms Elicited by Methylone and MDPV in Human Dopaminergic SH-SY5Y Cells.
Valente MJ; Bastos ML; Fernandes E; Carvalho F; Guedes de Pinho P; Carvalho M
ACS Chem Neurosci; 2017 Apr; 8(4):850-859. PubMed ID: 28067045
[TBL] [Abstract][Full Text] [Related]
4. Methylone and MDPV activate autophagy in human dopaminergic SH-SY5Y cells: a new insight into the context of β-keto amphetamines-related neurotoxicity.
Valente MJ; Amaral C; Correia-da-Silva G; Duarte JA; Bastos ML; Carvalho F; Guedes de Pinho P; Carvalho M
Arch Toxicol; 2017 Nov; 91(11):3663-3676. PubMed ID: 28527032
[TBL] [Abstract][Full Text] [Related]
5. Estrogen-related receptor gamma regulates dopaminergic neuronal phenotype by activating GSK3β/NFAT signaling in SH-SY5Y cells.
Lim J; Choi HS; Choi HJ
J Neurochem; 2015 May; 133(4):544-57. PubMed ID: 25727910
[TBL] [Abstract][Full Text] [Related]
6. Neuropharmacology of 3,4-Methylenedioxypyrovalerone (MDPV), Its Metabolites, and Related Analogs.
Baumann MH; Bukhari MO; Lehner KR; Anizan S; Rice KC; Concheiro M; Huestis MA
Curr Top Behav Neurosci; 2017; 32():93-117. PubMed ID: 27830575
[TBL] [Abstract][Full Text] [Related]
7. Cytotoxic Activity of Pyrovalerone Derivatives, an Emerging Group of Psychostimulant Designer Cathinones.
Wojcieszak J; Andrzejczak D; Woldan-Tambor A; Zawilska JB
Neurotox Res; 2016 Aug; 30(2):239-50. PubMed ID: 27295059
[TBL] [Abstract][Full Text] [Related]
8. Parkinson's disease cybrids, differentiated or undifferentiated, maintain morphological and biochemical phenotypes different from those of control cybrids.
Appukuttan TA; Ali N; Varghese M; Singh A; Tripathy D; Padmakumar M; Gangopadhyay PK; Mohanakumar KP
J Neurosci Res; 2013 Jul; 91(7):963-70. PubMed ID: 23653325
[TBL] [Abstract][Full Text] [Related]
9. Influence of serum concentration in retinoic acid and phorbol ester induced differentiation of SH-SY5Y human neuroblastoma cell line.
Magalingam KB; Radhakrishnan AK; Somanath SD; Md S; Haleagrahara N
Mol Biol Rep; 2020 Nov; 47(11):8775-8788. PubMed ID: 33098048
[TBL] [Abstract][Full Text] [Related]
10. Quantitative Characterization of Phenotypical Markers After Differentiation of SH-SY5Y Cells.
Ducray AD; Wiedmer L; Herren F; Widmer HR; Mevissen M
CNS Neurol Disord Drug Targets; 2020; 19(8):618-629. PubMed ID: 32640966
[TBL] [Abstract][Full Text] [Related]
11. RA Differentiation Enhances Dopaminergic Features, Changes Redox Parameters, and Increases Dopamine Transporter Dependency in 6-Hydroxydopamine-Induced Neurotoxicity in SH-SY5Y Cells.
Lopes FM; da Motta LL; De Bastiani MA; Pfaffenseller B; Aguiar BW; de Souza LF; Zanatta G; Vargas DM; Schönhofen P; Londero GF; de Medeiros LM; Freire VN; Dafre AL; Castro MA; Parsons RB; Klamt F
Neurotox Res; 2017 May; 31(4):545-559. PubMed ID: 28155214
[TBL] [Abstract][Full Text] [Related]
12. Linear pharmacokinetics of 3,4-methylenedioxypyrovalerone (MDPV) and its metabolites in the rat: relationship to pharmacodynamic effects.
Anizan S; Concheiro M; Lehner KR; Bukhari MO; Suzuki M; Rice KC; Baumann MH; Huestis MA
Addict Biol; 2016 Mar; 21(2):339-47. PubMed ID: 25475011
[TBL] [Abstract][Full Text] [Related]
13. 3,4-Methylenedioxypyrovalerone prevents while methylone enhances methamphetamine-induced damage to dopamine nerve endings: β-ketoamphetamine modulation of neurotoxicity by the dopamine transporter.
Anneken JH; Angoa-Pérez M; Kuhn DM
J Neurochem; 2015 Apr; 133(2):211-22. PubMed ID: 25626880
[TBL] [Abstract][Full Text] [Related]
14. 3,4-Methylenedioxypyrovalerone: Neuropharmacological Impact of a Designer Stimulant of Abuse on Monoamine Transporters.
Magee CP; German CL; Siripathane YH; Curtis PS; Anderson DJ; Wilkins DG; Hanson GR; Fleckenstein AE
J Pharmacol Exp Ther; 2020 Aug; 374(2):273-282. PubMed ID: 32385092
[TBL] [Abstract][Full Text] [Related]
15. Neurotoxicity of "ecstasy" and its metabolites in human dopaminergic differentiated SH-SY5Y cells.
Ferreira PS; Nogueira TB; Costa VM; Branco PS; Ferreira LM; Fernandes E; Bastos ML; Meisel A; Carvalho F; Capela JP
Toxicol Lett; 2013 Feb; 216(2-3):159-70. PubMed ID: 23194825
[TBL] [Abstract][Full Text] [Related]
16. Functional connectivity, behavioral and dopaminergic alterations 24 hours following acute exposure to synthetic bath salt drug methylenedioxypyrovalerone.
Colon-Perez LM; Pino JA; Saha K; Pompilus M; Kaplitz S; Choudhury N; Jagnarine DA; Geste JR; Levin BA; Wilks I; Setlow B; Bruijnzeel AW; Khoshbouei H; Torres GE; Febo M
Neuropharmacology; 2018 Jul; 137():178-193. PubMed ID: 29729891
[TBL] [Abstract][Full Text] [Related]
17. Effects of MDPV on dopamine transporter regulation in male rats. Comparison with cocaine.
Lopez-Arnau R; Duart-Castells L; Aster B; Camarasa J; Escubedo E; Pubill D
Psychopharmacology (Berl); 2019 Mar; 236(3):925-938. PubMed ID: 30284596
[TBL] [Abstract][Full Text] [Related]
18. Dopaminergic Effects of Major Bath Salt Constituents 3,4-Methylenedioxypyrovalerone (MDPV), Mephedrone, and Methylone Are Enhanced Following Co-exposure.
Allen SA; Tran LH; Oakes HV; Brown RW; Pond BB
Neurotox Res; 2019 Jul; 36(1):132-143. PubMed ID: 30879275
[TBL] [Abstract][Full Text] [Related]
19. Adverse outcome pathways induced by 3,4-dimethylmethcathinone and 4-methylmethcathinone in differentiated human SH-SY5Y neuronal cells.
Soares J; Costa VM; Gaspar H; Santos S; Bastos ML; Carvalho F; Capela JP
Arch Toxicol; 2020 Jul; 94(7):2481-2503. PubMed ID: 32382956
[TBL] [Abstract][Full Text] [Related]
20. Repeated exposure to 3,4-methylenedioxypyrovalerone and cocaine produces locomotor sensitization with minimal effects on brain monoamines.
Kohler RJ; Perrine SA; Baker LE
Neuropharmacology; 2018 May; 134(Pt A):22-27. PubMed ID: 29042316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
